Benefits
Hip and knee osteoarthritis pain (Christensen 2008 META-ANALYSIS PIVOTAL)
Christensen 2008 (PMID 18407528, Osteoarthritis Cartilage 16(9):965-972) — META-ANALYSIS of 3 randomized controlled trials. 287 patients with OA hip and/or knee (62% women, median age 66). 145 patients on rosehip powder vs 142 on placebo. Median trial duration 3 months. RESULTS: SIGNIFICANT PAIN REDUCTION effect size (ES) 0.37 (95% CI 0.13-0.60, p=0.002). HOMOGENEITY across trials (I²=0%) supporting consistent efficacy. Patients TWICE AS LIKELY to experience pain relief vs placebo. PATIENTS USED FEWER STANDARD ANALGESICS while on rosehip. Foundational pivotal evidence base.
Knee + hip OA double-blind RCT (Winther 2005 PMID 16195164)
Winther K, Apel K, Thamsborg G 2005 (PMID 16195164, Scand J Rheumatol 34(4):302-308) — randomized double-blind placebo-controlled clinical trial. Powder made from seeds and shells of Rosa canina subspecies REDUCES symptoms of knee and hip osteoarthritis. Foundational RCT in Scandinavian patients. One of three trials in Christensen 2008 meta-analysis.
Rheumatoid arthritis daily function + quality of life (Willich 2010)
Willich 2010 — randomized double-blind placebo-controlled trial. Rose-Hip improves daily function and quality of life in patients with RHEUMATOID ARTHRITIS (not just OA). Important indication beyond OA. Mechanism: anti-inflammatory effects via GOPO glycolipid. Inflammopharmacology and other journal publications support broader inflammatory joint applications.
Improved gait in knee mobility limitations (Stiebitz 2009)
Improved gait in persons with KNEE-RELATED MOBILITY LIMITATIONS by rosehip food supplement RCT. Mechanism: pain reduction + anti-inflammatory effects translating to functional gait improvements. Important functional outcome evidence beyond pain scores alone.
GOPO galactolipid anti-inflammatory mechanism (Schwager 2011)
Schwager 2011 — GOPO found in rose hips DECREASES INFLAMMATORY RESPONSES in: mouse macrophages, chondrocytes, peripheral blood leukocytes (PBLs). Distinct novel anti-inflammatory mechanism via specific galactolipid compound. Schwager characterized GOPO as the specific bioactive responsible for clinical anti-inflammatory effects. Foundational mechanism evidence.
LDL-cholesterol + C-Reactive Protein modulation
Hyben Vital trials documented EFFECTS on LDL-CHOLESTEROL and C-REACTIVE PROTEIN with rosehip supplementation. Cardiovascular + inflammatory marker improvements beyond joint-specific effects. Mechanism: anti-inflammatory + lipid modulating effects.
Reduced rescue analgesic use (multi-trial finding)
Multiple trials documented PATIENTS USED FEWER STANDARD ANALGESICS while supplementing with rosehip — practically meaningful outcome reflecting genuine pain relief efficacy. Important for those wanting NSAID alternatives or NSAID-sparing approaches.
Mechanism of action
GOPO (galactolipid) anti-inflammatory mechanism (UNIQUE)
GOPO — specific galactolipid (galactose-glycerol-fatty acid compound) IDENTIFIED as PRIMARY anti-inflammatory bioactive in rose hips. Inhibits chemotaxins and chemiluminescence of human peripheral blood neutrophils in vitro. Reduces inflammatory parameters in vivo. WITHOUT influencing platelet aggregation or coagulation cascade — distinct from NSAID/aspirin-like compounds. Mechanism for joint anti-inflammatory benefits without bleeding risks.
Polyunsaturated fatty acid omega-3/omega-6 content
Rosa canina contains omega-3 (alpha-linolenic acid) and omega-6 (linoleic acid) PUFAs. Mechanism contributing to anti-inflammatory effects. Complementary to GOPO galactolipid mechanism.
Vitamin C antioxidant + collagen synthesis cofactor
Rose hips are RICH source of vitamin C (10-15× more than oranges per gram). Vitamin C is collagen synthesis cofactor + antioxidant. Mechanism for joint matrix support + general antioxidant effects.
Anti-inflammatory without platelet/coagulation effects
Distinguishing pharmacology: anti-inflammatory effects WITHOUT influencing platelet aggregation or coagulation cascade. Mechanism allows long-term use without bleeding risks typical of NSAIDs.
Chondrocyte inflammatory response suppression
GOPO suppresses inflammatory responses specifically in CHONDROCYTES (cartilage cells). Mechanism for direct cartilage protection in OA — relevant to disease-modifying potential beyond pure pain relief.
Polyphenol/flavonoid antioxidant synergy
Multi-component polyphenol/flavonoid antioxidant profile complements GOPO + PUFA + vitamin C effects. Comprehensive antioxidant matrix.
Clinical trials
Meta-analysis of randomized controlled trials (Christensen R, Bartels EM, Altman RD, Astrup A, Bliddal H 2008, Osteoarthritis Cartilage 16(9):965-972, doi:10.1016/j.joca.2008.03.001, PMID 18407528).
Pooled analysis of 3 RCTs supported by Hyben-Vital International. 287 patients with hip and/or knee osteoarthritis (62% women, median age 66). 145 patients on rosehip powder (5 g/day) vs 142 on placebo. Median trial duration 3 months.
SIGNIFICANT PAIN REDUCTION effect size (ES) 0.37 (95% CI 0.13-0.60, p=0.002). Test for HOMOGENEITY supported consistent efficacy across trials (I²=0%). Patients TWICE AS LIKELY to experience pain relief with rosehip vs placebo. Number Needed to Treat analysis supported clinical relevance. Patients USED FEWER STANDARD ANALGESICS while on rosehip. INDUSTRY-SPONSORED (Hyben-Vital International) — important context for evidence interpretation.
Randomized double-blind placebo-controlled clinical trial (Winther K, Apel K, Thamsborg G 2005, Scand J Rheumatol 34(4):302-308, doi:10.1080/03009740510018624, PMID 16195164).
Patients with knee and hip osteoarthritis. Powder made from seeds and shells of Rosa canina subspecies vs placebo. Conducted in Scandinavia.
ROSEHIP POWDER REDUCES SYMPTOMS of KNEE AND HIP OSTEOARTHRITIS. Foundational positive RCT. One of three trials included in Christensen 2008 meta-analysis. INDUSTRY-RELATED (Hyben-Vital International) — important context.
Randomized double-blind placebo-controlled clinical trial (Rein E, Kharazmi A, Winther K 2004, Phytomedicine 11(5):383-391).
Patients with osteoarthritis. Hyben Vital (standardized powder of Rosa canina subspecies fruits) vs placebo. Outpatient clinic populations in Denmark.
ROSEHIP HERBAL REMEDY REDUCES PAIN AND IMPROVES GENERAL WELLBEING in patients with osteoarthritis. Foundational RCT. One of three trials in Christensen 2008 meta-analysis. INDUSTRY-RELATED context noted.
About this ingredient
GOPO® Rosehip is a STANDARDIZED POWDER from Rosa canina L. (specific subspecies) seeds and shells, manufactured by HYBEN VITAL INTERNATIONAL (Denmark — Tullebølle, Langeland). Active compound: GOPO (Galactolipid Of Pomegranate Origin... specifically a galactolipid identified in rosehip; the (2S)-1,2-di-O-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]-3-O-β-D-galactopyranosyl glycerol). Multi-component: GOPO + polyunsaturated omega-3 (alpha-linolenic acid) + omega-6 (linoleic acid) PUFAs + HIGH VITAMIN C content (10-15× more than oranges per gram) + flavonoids + phenolic acids. CLINICAL EVIDENCE BASE: CHRISTENSEN 2008 PMID 18407528 (Osteoarthritis Cartilage 16(9):965-972) PIVOTAL META-ANALYSIS of 3 RCTs (n=287 OA hip/knee patients, 5 g/day, 3-month median duration) — significant pain reduction effect size 0.37 (95% CI 0.13-0.60, p=0.002) with homogeneous efficacy across trials (I²=0%); patients TWICE AS LIKELY to experience pain relief vs placebo; PATIENTS USED FEWER STANDARD ANALGESICS while on rosehip. WINTHER 2005 PMID 16195164 (Scand J Rheumatol) — foundational knee + hip OA RCT. REIN 2004 (Phytomedicine 11(5):383-391) — Hyben Vital reduces pain and improves wellbeing in OA. WARHOLM 2003 (Curr Ther Res Clin Exp 64:21-31) — Norway-based standardized rosehip OA RCT. WILLICH 2010 — RHEUMATOID ARTHRITIS daily function + quality of life RCT (broader indication). STIEBITZ et al. — improved gait in persons with knee-related mobility limitations. SCHWAGER 2011 — GOPO mechanism characterization (chemotaxin + chemiluminescence inhibition in neutrophils, anti-inflammatory effects in macrophages, chondrocytes, PBLs). Hyben Vital research base + Inflammopharmacology publications. UNIQUE PHARMACOLOGY: rosehip exerts anti-inflammatory properties WITHOUT influencing platelet aggregation or coagulation cascade — distinguishing safety advantage vs NSAID-class compounds.
MECHANISMS: GOPO galactolipid anti-inflammatory mechanism (UNIQUE among joint supplements); polyunsaturated fatty acids; vitamin C antioxidant + collagen synthesis cofactor; chondrocyte inflammatory response suppression (direct cartilage protection); polyphenol/flavonoid antioxidant synergy; NO platelet/coagulation effects (safety advantage). EVIDENCE: 3/5 reflects: (1) CHRISTENSEN 2008 PIVOTAL META-ANALYSIS with statistically significant effect size + homogeneity across 3 RCTs, (2) WINTHER 2005 PIVOTAL knee + hip OA RCT, (3) REIN 2004 Hyben Vital Phytomedicine RCT, (4) WILLICH 2010 RHEUMATOID ARTHRITIS quality of life RCT (broader indication beyond OA), (5) SCHWAGER 2011 mechanism characterization, (6) WELL-CHARACTERIZED unique GOPO galactolipid mechanism distinct from NSAID-like compounds, (7) NUMBER NEEDED TO TREAT analysis supports clinical relevance, (8) industry-sponsored evidence (Hyben-Vital International) noted explicitly in Christensen 2008 — important context for interpretation, (9) EXTENSIVE Scandinavian/European traditional use base. SAFETY: Excellent — food-grade origin + extensive clinical safety record + NO platelet/coagulation effects. Best positioned as: (a) HIP AND KNEE OSTEOARTHRITIS adjunct or alternative to NSAIDs (Christensen 2008 PIVOTAL meta-analysis evidence), (b) RHEUMATOID ARTHRITIS adjunct (Willich 2010 evidence), (c) GAIT/MOBILITY in knee limitations (Stiebitz evidence), (d) NSAID-SPARING strategy for those wanting reduced NSAID requirement, (e) ANTI-INFLAMMATORY for those on anticoagulants (NO platelet effects — distinguishing safety advantage), (f) DAILY long-term use acceptable based on safety profile + extensive food consumption history, (g) higher-evidence than typical 'rosehip supplement' due to standardization + meta-analysis evidence + GOPO mechanism characterization. Honest framing: GOPO® Rosehip has more rigorous evidence than typical rosehip supplements — Christensen 2008 meta-analysis with statistically significant effect size across 3 RCTs is methodologically robust evidence rare among herbal supplements. The GOPO galactolipid mechanism is biochemically distinctive — Schwager 2011 characterization is real mechanism evidence. The NO platelet/coagulation effects safety advantage is clinically meaningful for those needing anti-inflammatory effects without bleeding risks. Industry-sponsorship (Hyben-Vital International) of all 3 trials in Christensen 2008 warrants caveat (authors explicitly recommend trials with other manufacturers in future). Reasonable joint health adjunct based on evidence — particularly compelling for those with OA seeking NSAID alternatives or anti-inflammatory support without bleeding concerns.